Lewes, DE -- (SBWire) -- 06/12/2015 --Report forecast the infectious diseases market in US to grow at a CAGR of 3.37% over the period 2014-2019.
Human beings are prone to various kinds of infections. Infectious diseases are caused by various pathogenic microorganisms such as bacteria, fungi, parasites, and viruses. Antimicrobials are used to treat infections. They act by killing or resisting the growth of the microorganisms. They either act via the host defense system or directly target the causative agent. Based on the target organism, antimicrobials can be classified into anti-bacterial, anti-viral, anti-fungal, and anti-parasitic drugs.
This report covers the present scenario and the growth prospects of the infectious diseases market in US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of drugs administered to treat infectious diseases caused by bacteria, viruses, fungi, and parasites.
The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the infectious diseases market in US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
According to the report, the increased patient population with hepatitis and HIV propels market growth. The surge in infectious diseases results in the increased consumption of medicines.
Infectious Diseases Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. In addition, it discusses the major drivers that influence the growth of the market, challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.
Key players in the infectious diseases market in the US: F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck and Pfizer
Other Prominent Vendors in the market are: AbbVie, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Sanofi and Vertex
Market Driver
- Rise in patient population
- For a full, detailed list, view our report
Market Challenge
- Generic erosion
- For a full, detailed list, view our report
Market Trend
- Emergence of IFN-free therapies
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Spanning over 111 pages, "Infectious Diseases Market in US 2015-2019" report covers Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Epidemiology, Market Segmentation by Type of Drug, Market Segmentation by Route of Administration, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis.
For further information on this report, please visit- http://www.marketresearchreports.com/technavio/infectious-diseases-market-us-2015-2019
Find all Diseases Reports at: http://www.marketresearchreports.com/diseases
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter
